Ponatinib is a highly potent tyrosine kinase inhibitor shown to have excellent outcomes in the treatment of acute and chronic leukemias. Despite its high efficacy, ponatinib has been shown to carry an increased risk for cardiovascular adverse events, not attributable to a known mechanism. We present a case of a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) who developed a cerebrovascular condition while receiving maintenance therapy with the lowest treatment dose of ponatinib for a prolonged duration.
Keywords: bcr-abl; optimizing ponatinib treatment in chronic phase-chronic myelogenous leukemia; ponatinib; ponatinib ph+ acute lymphoblastic leukemia and chronic myelogenous leukemia evaluation; tyrosine kinase inhibitors.
Copyright © 2022, Azad et al.